Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 2
1992 7
1993 7
1994 5
1995 2
1996 9
1997 6
1998 4
1999 6
2000 7
2001 1
2002 1
2003 4
2004 2
2005 3
2006 8
2007 7
2008 7
2009 4
2010 6
2011 6
2012 9
2013 5
2014 8
2015 7
2016 9
2017 5
2018 7
2019 10
2020 8
2021 6
2022 5
2023 5
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

179 results

Results by year

Filters applied: . Clear all
Page 1
ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease†.
Colombo N, Sessa C, du Bois A, Ledermann J, McCluggage WG, McNeish I, Morice P, Pignata S, Ray-Coquard I, Vergote I, Baert T, Belaroussi I, Dashora A, Olbrecht S, Planchamp F, Querleu D; ESMO-ESGO Ovarian Cancer Consensus Conference Working Group. Colombo N, et al. Ann Oncol. 2019 May 1;30(5):672-705. doi: 10.1093/annonc/mdz062. Ann Oncol. 2019. PMID: 31046081 Free article.
Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial.
Pfisterer J, Shannon CM, Baumann K, Rau J, Harter P, Joly F, Sehouli J, Canzler U, Schmalfeldt B, Dean AP, Hein A, Zeimet AG, Hanker LC, Petit T, Marmé F, El-Balat A, Glasspool R, de Gregorio N, Mahner S, Meniawy TM, Park-Simon TW, Mouret-Reynier MA, Costan C, Meier W, Reinthaller A, Goh JC, L'Haridon T, Baron Hay S, Kommoss S, du Bois A, Kurtz JE; AGO-OVAR 2.21/ENGOT-ov 18 Investigators. Pfisterer J, et al. Among authors: zeimet ag. Lancet Oncol. 2020 May;21(5):699-709. doi: 10.1016/S1470-2045(20)30142-X. Epub 2020 Apr 16. Lancet Oncol. 2020. PMID: 32305099 Free article. Clinical Trial.
Ovarian Cancer Stem Cell Heterogeneity.
Hatina J, Boesch M, Sopper S, Kripnerova M, Wolf D, Reimer D, Marth C, Zeimet AG. Hatina J, et al. Among authors: zeimet ag. Adv Exp Med Biol. 2019;1139:201-221. doi: 10.1007/978-3-030-14366-4_12. Adv Exp Med Biol. 2019. PMID: 31134503 Review.
Hopes and failures in front-line ovarian cancer therapy.
Tsibulak I, Zeimet AG, Marth C. Tsibulak I, et al. Among authors: zeimet ag. Crit Rev Oncol Hematol. 2019 Nov;143:14-19. doi: 10.1016/j.critrevonc.2019.08.002. Epub 2019 Aug 14. Crit Rev Oncol Hematol. 2019. PMID: 31449982 Free article. Review.
179 results